Olipass
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Olipass is a South Korean biotech, listed on KOSDAQ, developing RNA-based medicines, drugs that work by silencing the genetic instructions that cause disease rather than targeting the disease protein directly.
Its lead programme is a non-opioid painkiller designed to selectively suppress a sodium-ion channel gene linked to pain perception, an approach intended to avoid the serious side effects seen with conventional small-molecule pain drugs. The company's core platform, built around its proprietary chemically modified nucleic-acid molecule called OPNA, is designed to be applicable across multiple disease areas, and it is also developing a treatment for ALS (Lou Gehrig's disease).
Summary is AI-generated and may contain errors · figures from DART filings
Olipass in five facts
What does Olipass do?
Olipass is a South Korean biotech, listed on KOSDAQ, developing RNA-based medicines, drugs that work by silencing the genetic instructions that cause disease rather than targeting the disease protein directly.
Where is Olipass listed and in which sector?
Olipass (Korean name: 올리패스) trades under KRX code 244460 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Olipass?
Its market capitalisation was US$10.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Olipass's latest annual revenue and operating profit?
For fiscal year 2025, Olipass reported revenue of US$615.9K, an operating loss of US$5.6M and a net loss of US$11.6M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 7.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.